

CONFERENCE PROGRAM

SUNDAY, APRIL 23

3:00 p.m.-8:30 p.m.

Registration

Harbor Ballroom Foyer

7:00 p.m.-8:30 p.m.

Welcome and Keynote Address

Harbor Ballroom BC

7:00 p.m.-7:15 p.m.

Introduction and Welcome

Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, TX

Jennifer Rubin Grandis, University of California, San Francisco, CA

J. Silvio Gutkind, UCSD Moores Cancer Center, La Jolla, CA

Quynh-Thu Le, Stanford Cancer Institute, Palo Alto, CA

7:15 p.m.-7:45 p.m.

Head and neck cancer research: Historical perspectives over four decades

Waun Ki Hong, The University of Texas MD Anderson Cancer Center, Houston, TX

7:45 p.m.-8:30 p.m.

Keynote address

Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX

8:30 p.m.-10:00 p.m.

Reception

Harbor Ballroom A & Foyer

MONDAY, APRIL 24

6:30 a.m.-6:00 p.m.

Registration

Harbor Ballroom Foyer

7:00 a.m.-8:00 a.m.

Continental Breakfast

Harbor Ballroom A & Foyer

8:00 a.m.-9:15 a.m.

Plenary Session 1: Detection and Prevention

Harbor Ballroom BC

Session Chair: William N. William, Jr., The University of Texas MD Anderson Cancer Center, Houston, TX

8:00 a.m.-8:25 a.m.

Detection of tumor DNA in the saliva and plasma of patients with HNSCC

Nishant Agrawal, University of Chicago Pritzker School of Medicine, Chicago, IL

8:25 a.m.-8:50 a.m.

Oral cancer prevention

Joseph A. Califano, University of California, San Diego, La Jolla, CA

8:50 a.m.-9:15 a.m.

Immunoprevention of oral cancers

William N. William, Jr.

CONFERENCE PROGRAM

9:15 a.m.-9:35 a.m.	Break Harbor Ballroom Foyer
9:35 a.m.-10:50 a.m.	Plenary Session 2: Novel Targets and Biomarkers in Head and Neck Cancer Harbor Ballroom BC Session Chair: Eduardo Mendez , University of Washington, Seattle, WA
9:35 a.m.-10:00 a.m.	Identification of Wee-1 as a potential target for treating head and neck cancer and clinical evaluation of a Wee-1 inhibitor Eduardo Mendez
10:00 a.m.-10:25 a.m.	Head and neck squamous cell cancer stem cells: Harnessing oncogenic signaling to enable tumorigenicity Antonio Jimeno, University of Colorado Cancer Center, Aurora, CO
10:25 a.m.-10:50 a.m.	Personalizing HNSCC treatment based on TP53 mutational status Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, TX
10:50 a.m.-11:50 a.m.	Short talks from proffered abstracts Harbor Ballroom BC Session Chair: Jeffrey N. Myers , The University of Texas MD Anderson Cancer Center, Houston, TX
10:50 a.m.-11:00 a.m.	Genomic and functional correlates from a phase II clinical trial of trametinib in surgically resectable oral cavity squamous cell carcinoma Paul Zolkind, Washington University School of Medicine, St. Louis, MO
11:00 a.m.-11:10 a.m.	DeSigN identifies CDK4/6 inhibitors for the treatment of head and neck cancer Sok Ching Cheong, Cancer Research Malaysia, Subang Jaya, Malaysia
11:10 a.m.-11:20 a.m.	Single cell RNA-seq reveals malignant and stromal programs associated with invasion and metastasis in head and neck cancer Sidharth Venkata Puram, Massachusetts Eye and Ear Infirmary, Boston, MA
11:20 a.m.-11:30 a.m.	HER3 crosstalk with HPV16-E6E7 is a feedback resistance mechanism to PI3K-targeted therapies in head and neck cancer Toni M. Brand, University of California, San Francisco, CA
11:30 a.m.-11:40 a.m.	Adaptive chemo-radiotherapy for head and neck cancer based on multiparametric MRI: Interim results of a prospective randomized trial Avraham Eisbruch, University of Michigan Health System, Ann Arbor, MI
11:40 a.m.-11:50 a.m.	The effect of low-dose fractionated versus high-dose hypofractionated radiotherapy on antitumor immunity Megan V. Morisada, NIH-NIDCD, Bethesda, MD
11:50 a.m.-1:45 p.m.	Lunch on own

CONFERENCE PROGRAM

- 1:45 p.m.-3:25 p.m.** **Plenary Session 3: Cancer Genomics and Signatures of Mutational Processes in Human Cancer**
Harbor Ballroom BC
Session Chair: Jennifer Rubin Grandis, University of California, San Francisco, CA
- 1:45 p.m.-2:10 p.m. Comprehensive genomic characterization of head and neck squamous cell carcinomas
Jennifer Rubin Grandis
- 2:10 p.m.-2:35 p.m. Integrated omics analyses identify prognostic biomarkers of oral cavity squamous cell carcinoma in Taiwan
Kai-Ping Chang, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- 2:35 p.m.-3:00 p.m. Interactions between the genome and immune microenvironment in head and neck cancer
Luc G. T. Morris, Memorial Sloan Kettering Cancer Center, New York, NY
- 3:00 p.m.-3:25 p.m. An in vivo high throughput shRNA screening platform for identifying ways to target genomic alterations
Mitchell J. Frederick, Baylor College of Medicine, Houston, TX
- 3:30 p.m.-6:00 p.m.** **Poster Session/Reception**
Harbor Ballroom DEF
- 6:00 p.m.-** **Evening off/Dinner on own**

TUESDAY, APRIL 25

- 6:30 a.m.-4:15 p.m.** **Registration**
Harbor Ballroom Foyer
- 7:00 a.m.-8:00 a.m.** **Continental Breakfast**
Harbor Ballroom A & Foyer
- 8:00 a.m.-9:40 a.m.** **Plenary Session 4: Breakthroughs in Imaging Head and Neck Cancers**
Harbor Ballroom BC
Session Chair: Quyen T. Nguyen, University of California, San Diego, CA
- 8:00 a.m.-8:25 a.m. Real-time near-infrared fluorescence tracer imaging to guide sentinel node biopsy and tumor detection in head and neck cancer
Christian Von Buchwald, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
- 8:25 a.m.-8:50 a.m. Optimizing head and neck cancer treatment outcomes with MRI
Stephen Y. Lai, The University of Texas MD Anderson Cancer Center, Houston, TX

CONFERENCE PROGRAM

Plenary Session 4 (cont'd)

- 8:50 a.m.-9:15 a.m. Molecular navigation for cancer diagnosis and surgery: Imaging tumors and nerves
Quyen T. Nguyen
- 9:15 a.m.-9:40 a.m. Midtreatment metabolic imaging as a biomarker of treatment response
Quynh-Thu Le, Stanford Cancer Institute, Palo Alto, CA
- 9:40 a.m.-10:00 a.m. Break**
Harbor Ballroom Foyer
- 10:00 a.m.-11:40 a.m. Plenary Session 5: Clinical Management/Outcomes/Survivorship/Disparities**
Harbor Ballroom BC
Session Chair: Harry Quon, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
- 10:00 a.m.-10:25 a.m. Treatment de-intensification strategies for head and neck cancer
Barbara A. Burtness, Smilow Cancer Hospital/Yale Cancer Center, New Haven, CT
- 10:25 a.m.-10:50 a.m. Optimizing oncologic outcomes and swallowing function with radiotherapy
Harry Quon
- 10:50 a.m.-11:15 a.m. Clinical and imaging methods for grading and predicting dysphagia in patients with head and neck cancer
Katherine A. Hutcheson, The University of Texas MD Anderson Cancer Center, Houston, TX
- 11:15 a.m.-11:40 a.m. Oncologic and quality-of-life outcomes for patients with oropharyngeal cancer treated with robotic surgery or definitive chemoradiotherapy
Umamaheswar Duvvuri, University of Pittsburgh School of Medicine, Pittsburgh, PA
- 11:40 a.m.-1:00 p.m. Lunch on own**
- 1:00 p.m.-2:40 p.m. Plenary Session 6: Immune Checkpoint Blockade in Cancer Therapies/ Immunobiology/Targeting the Immune System**
Harbor Ballroom BC
Session Chair: Robert L. Ferris, University of Pittsburgh Cancer Institute, Pittsburgh, PA
- 1:00 p.m.-1:25 p.m. Immunocompetent models of head and neck cancer
Ravindra Uppaluri, Dana-Farber Cancer Institute, Boston, MA
- 1:25 p.m.-1:50 p.m. Myeloid derived suppressor cells as mediators of local immune suppression in head and neck cancer
Clint T. Allen, National Institutes of Health, Bethesda, MD
- 1:50 p.m.-2:15 p.m. Immunotherapy for head and neck cancer
Robert L. Ferris
- 2:15 p.m.-2:40 p.m. Biomarkers and checkpoint inhibition in HNSCC
Ezra E. W. Cohen, UCSD Moores Cancer Center, La Jolla, CA

CONFERENCE PROGRAM

2:45 p.m.-4:00 p.m.	Plenary Session 7: Viral Cancers HPV/EBV Harbor Ballroom BC Session Chair: Maura L. Gillison , The University of Texas MD Anderson Cancer Center, Houston, TX
2:45 p.m.-3:10 p.m.	Differences in oral HPV natural history, risk factors, and OPSCC, by sex Gypsyamber D'Souza, Johns Hopkins University, Baltimore, MD
3:10 p.m.-3:35 p.m.	HPV infection, genomic instability, and outcome in OPSCC Maura L. Gillison
3:35 p.m.-4:00 p.m.	Current perspectives on the treatment of nasopharyngeal carcinoma (NPC) Anthony T. Chan, Chinese University of Hong Kong, Hong Kong, SAR
4:00 p.m.-4:15 p.m.	Summary and Closing remarks Harbor Ballroom BC
4:00 p.m.-4:10 p.m.	Summary J. Silvio Gutkind, UCSD Moores Cancer Center, La Jolla, CA
4:10 p.m.-4:15 p.m.	Closing Remarks Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, TX